SAB Biotherapeutics, Inc. Cash Flow Statement
SABS|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
SAB Biotherapeutics, Inc. used $34M in operating cash flow and negative free cash flow of $35M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.31 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$34.1M | -$42.2M | -$18.7M | -$17.1M | $20.1M |
| Depreciation & Amortization | $4.7M | $3.7M | $3.2M | $1.5M | $383.1K |
| Operating Cash Flow | -$34.3M | -$25.1M | -$23.5M | $2.0M | $10.0M |
| Capital Expenditures | $337.3K | $197.2K | $2.2M | $10.9M | $12.7M |
| Free Cash Flow | -$34.6M | -$25.3M | -$25.6M | -$9.0M | -$2.7M |
| FCF Margin | -2618.7% | -1130.7% | -107.2% | -14.7% | -4.9% |